title: Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO).
abstract: Diffuse large B-cell lymphoma patients have a 5% overall risk of central nervous system events (relapse or progression), which account for high morbidity and frequently fatal outcomes,1and shortened overall survival of <6 months.2Early diagnosis of central nervous system events is critical for successful treatment and improved prognosis. Identification of patients at risk of central nervous system disease is critical to accurately identify candidates for central nervous system prophylaxis vs.
  
  
  
  3-5This report by the Spanish Lymphoma Group (GELTAMO) aims to provide useful guidelines and recommendations for the prevention, diagnosis, and treatment of central nervous system diffuse large B-cell lymphoma patients with, or at risk of, leptomeningeal and/or brain parenchyma lymphoma relapse. A panel of lymphoma experts working on behalf of GELTAMO reviewed all data published on these topics available in PubMed up to May 2016. Recommendations were classified according to the Grading of Recommendations Assessment Development and Evaluation (GRADE) approach.6A practical algorithm based on the proposed recommendations was then developed (Figure 1). Initial discussions among experts were held in May 2014, and final consensus was reached in June 2016. The final manuscript was reviewed by all authors and the Scientific Committee of GELTAMO.
authors.affiliation: Department of Hematology, Hospital Universitario Fundación Alcorcón, Madrid, Spain fjpenalver@fhalcorcon.es.
authors.forename: Francisco-Javier
authors.initials: FJ
authors.lastname: Peñalver
authors.affiliation: Clinical Hematology Department, ICO-IJC Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.
authors.forename: Juan-Manuel
authors.initials: JM
authors.lastname: Sancho
authors.affiliation: Department of Hematology, MD Anderson Cancer Center, Madrid, Spain.
authors.forename: Adolfo
authors.initials: A
authors.lastname: de la Fuente
authors.affiliation: Department of Hematology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
authors.forename: María-Teresa
authors.initials: MT
authors.lastname: Olave
authors.affiliation: Department of Hematology, Hospital Universitario de Salamanca, Department of Medicine, Cytometry Service (NUCLEUS) and Cancer Research Center (IBMCC-USAL-CSIC) and IBSAL, University of Salamanca, Pamplona, Spain.
authors.forename: Alejandro
authors.initials: A
authors.lastname: Martín
authors.affiliation: Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain.
authors.forename: Carlos
authors.initials: C
authors.lastname: Panizo
authors.affiliation: Department of Hematology, Hospital General Universitario Morales Meseguer, Murcia, Spain.
authors.forename: Elena
authors.initials: E
authors.lastname: Pérez
authors.affiliation: Department of Hematology, Hospital del Mar, Barcelona, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Salar
authors.affiliation: Department of Hematology, Hospital Universitario de Salamanca, Department of Medicine, Cytometry Service (NUCLEUS) and Cancer Research Center (IBMCC-USAL-CSIC) and IBSAL, University of Salamanca, Pamplona, Spain.
authors.forename: Alberto
authors.initials: A
authors.lastname: Orfao
mesh_terms: D015415:Biomarkers; D001706:Biopsy; D016543:Central Nervous System Neoplasms / Q000175:diagnosis* / Q000517:prevention & control / Q000556:secondary* / Q000628:therapy*; D018890:Chemoprevention; D003131:Combined Modality Therapy; D019468:Disease Management; D006801:Humans; D016130:Immunophenotyping; D016403:Lymphoma, Large B-Cell, Diffuse / Q000473:pathology*; D064847:Multimodal Imaging; D012307:Risk Factors; D013030:Spain
chemical_list: D015415:Biomarkers